Found 165 cancer-center trials
A listing of cancer-center medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas
An Open-Label, Multicenter, First-in-Human, Dose-Escalation Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas.
Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination with Pembrolizumab in Subjects with Selected Advanced Solid Tumors (DUET-4)
Phase 1
This is a Phase 1, multiple-dose, ascending dose-escalation and expansion study of XmAb22841, both as a monotherapy and in combination with pembrolizumab. The study is designed in 2 parts, Part A and Part B. Part A is a 3 + 3 dose escalation designed to assess both XmAb22841 administered as …
Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53
Phase 1
ASTX295 is a synthetic small molecule that acts as an antagonist of Murine Double Minute 2 (MDM2; human homolog also known as HDM2). Study ASTX295-01 is a study with ASTX295 in subjects who are refractory or have relapsed after treatment with standard of care therapies, or for whom standard life-prolonging …
Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
Phase 2
This study is being done to evaluate if participants with HER2-positive breast cancer who have no cancer remaining at surgery after 12 weeks of chemotherapy and two HER-targeting therapies eliminate further chemotherapy after surgery. Eligible subjects would be those with HER2-positive breast cancer.
Study Evaluating Safety and Efficacy of UCART123 in Patients With Relapsed/ Refractory Acute Myeloid Leukemia (AMELI-01)
Phase 1
This study is evaluating the safety and efficacy of UCART targeting CD123 in patients with relapsed/refractory acute myeloid leukemia (AML). The purpose of this study is to evaluate the safety and clinical activity of UCART123v1.2 and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D).
Phase Ia/Ib Dose-Escalation and Dose-Expansion Study Evaluating the Safety Pharmacokinetics and Activity of GDC-6036 as a Single Agent and in Combination With Other Anti-cancer Therapies in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
Phase 1
This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.
Durvalumab (MEDI4736) with Chemotherapy as First Line Treatment in Advanced Pleural Mesothelioma
Phase 3
Patients with malignant pleural mesothelioma (MPM) that cannot be surgically removed will receive first-line treatment with standard chemotherapy of cisplatin or carboplatin and pemetrexed. T Durvalumab is an antibody (a type of human protein) that works by blocking a body substance called Programmed Death-Ligand 1 (PD-L1). Blocking PD-L1 helps the …
CAR-T Followed by Bispecific Antibodies
Phase 2
The research study is being conducted to test the safety and effectiveness of the experimental drug mosunetuzumab or obinutuzumab and glofitamab (Cohort 2) when given after CAR (genetically modified) T cells. The study is for patients who have already received a CAR T-cell infusion. Some patients who join the study …
Study of Sacituzumab Govitecan With or Without Pembrolizumab in PD-L1-Negative Metastatic Triple Negative Breast Cancer (TNBC)
Phase 2
This is a randomized phase 2 open label study of sacituzumab govitecan +/- pembrolizumab for patients with PD-L1-negative (PD-L1-) metastatic triple negative breast cancer (TNBC), who have not received prior therapy for metastatic breast cancer and who have not received a prior PD-1/L1 inhibitor
Testing novel drugs or drug combinations to treat breast cancer before surgery
A clinical trial to determine whether adding experimental agents to standard neoadjuvant paclitaxel (with or without trastuzumab), anthracycline, nad cyclosphosphamide increases the probability of pathologic complete response (pCR) over standard neoadjuvant chemotherapy for each biomarker signature established at trial entry, and to determine for each experimental agent used, the predictive …
